First Patient Dosed in Phase 3 STOP-HAE Trial of ADX-324 ADX-324, a next-generation siRNA therapeutic for HAE, has entered phase 3 development with the first patient dosed in the STOP-HAE trial.

#ADX324, a next-generation small interference (#siRNA) therapeutic for hereditary angioedema (#HAE), has received #OrphanDrug Designation from the US FDA and entered phase 3 development, with the first patient dosed in the #STOPHAE trial.

Read more: https://bit.ly/43hyVPt

#RareDisease #MedSky